Additionally, large-scale real-world studies indicate that GLP-1 class drugs may cause severe adverse reactions, such as acute pancreatitis, cholelithiasis, and acute kidney injury [[32], [33], [34], [35]]. The gene discussed is GLP1R; the disease is cholelithiasis.